Targeting this pathway with PI3K inhibitors—such as PI-103, PX-866, NVP-BEZ235, Alpelisib, and Buparlisib—has shown considerable promise in preclinical studies by reducing tumor growth, enhancing apoptosis, and overcoming therapeutic resistance. This evidence concerns the gene PIK3CA and neoplasm.